PubRank

Charles L Bennett

Author PubWeight™ 211.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006 11.26
2 Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007 4.97
3 Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009 4.74
4 Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002 4.69
5 High rates of adverse drug events in a highly computerized hospital. Arch Intern Med 2005 4.68
6 Low literacy impairs comprehension of prescription drug warning labels. J Gen Intern Med 2006 4.01
7 Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007 3.91
8 Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2007 3.85
9 The association of health literacy with cervical cancer prevention knowledge and health behaviors in a multiethnic cohort of women. Am J Obstet Gynecol 2002 3.63
10 Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2005 3.38
11 Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009 3.26
12 Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006 3.23
13 Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med 2008 3.07
14 Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009 3.07
15 Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002 3.05
16 Social stigma concerns and HIV medication adherence. AIDS Patient Care STDS 2006 3.02
17 Unintended consequences of health information technology: evidence from veterans affairs colorectal cancer oncology watch intervention. J Clin Oncol 2012 2.67
18 Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007 2.43
19 Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004 2.33
20 The financial burden of cancer: estimates from a study of insured women with breast cancer. J Support Oncol 2004 2.30
21 Colorectal cancer screening knowledge, attitudes, and beliefs among veterans: does literacy make a difference? J Clin Oncol 2004 2.27
22 Literacy, self-efficacy, and HIV medication adherence. Patient Educ Couns 2006 2.18
23 Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol 2009 2.16
24 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010 2.16
25 Health care provider-directed intervention to increase colorectal cancer screening among veterans: results of a randomized controlled trial. J Clin Oncol 2005 2.10
26 Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology 2013 2.04
27 Development and validation of a short-form, rapid estimate of adult literacy in medicine. Med Care 2007 2.04
28 Costs and cost-effectiveness of a low-intensity patient-directed intervention to promote colorectal cancer screening. J Clin Oncol 2007 1.91
29 Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 2004 1.78
30 Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 2014 1.76
31 Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008 1.73
32 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010 1.68
33 A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report. J Oncol Pract 2012 1.63
34 Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 2006 1.59
35 Literacy, race, and PSA level among low-income men newly diagnosed with prostate cancer. Urology 2006 1.57
36 Post-cardiac catheterization access site complications and low-molecular -weight heparin following cardiac catheterization. J Invasive Cardiol 2003 1.55
37 Legal, financial, and public health consequences of HIV contamination of blood and blood products in the 1980s and 1990s. Ann Intern Med 2002 1.54
38 Finishing the picture: problems with public reporting of clinical trials. J Clin Oncol 2013 1.52
39 Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol 2003 1.50
40 Czech health two decades on from the Velvet Revolution. Lancet 2009 1.49
41 Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer 2008 1.48
42 Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect. Ann Intern Med 2002 1.45
43 American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004 1.44
44 Colorectal cancer screening among African-American and white male veterans. Am J Prev Med 2005 1.39
45 Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2006 1.36
46 Patient preferences in prostate cancer: a clinician's guide to understanding health utilities. Clin Prostate Cancer 2005 1.33
47 Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica 2010 1.27
48 Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans. J Clin Oncol 2005 1.27
49 Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. Surgery 2003 1.24
50 Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. Cancer 2006 1.19
51 Development of a brief survey on colon cancer screening knowledge and attitudes among veterans. Prev Chronic Dis 2005 1.13
52 Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008 1.10
53 Prediction rule for atrial fibrillation after major noncardiac thoracic surgery. Ann Thorac Surg 2005 1.10
54 Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012 1.06
55 Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int 2011 1.03
56 Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002 1.02
57 A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics 2009 1.01
58 The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int 2013 1.01
59 Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl 2009 1.00
60 Providing cancer care to a graying and diverse cancer population in the 21st century: are we prepared? J Clin Oncol 2009 1.00
61 Acting on imperfect evidence: How much regret are we ready to accept? J Clin Oncol 2005 0.99
62 G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007 0.99
63 Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. Drug Saf 2009 0.99
64 Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006 0.98
65 Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist 2007 0.98
66 Improving mammography screening among the medically underserved. J Gen Intern Med 2013 0.98
67 Systematic review of piperacillin-induced neutropenia. Drug Saf 2007 0.97
68 A qualitative study of literacy and patient response to HIV medication adherence questionnaires. J Health Commun 2005 0.96
69 The sound and the fury: financial conflicts of interest in oncology. J Clin Oncol 2007 0.96
70 Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res 2009 0.96
71 Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer 2002 0.96
72 Amiodarone-associated optic neuropathy: a critical review. Am J Med 2012 0.93
73 Studying cancer-related fatigue: report of the NCCN scientific research committee. J Natl Compr Canc Netw 2010 0.93
74 Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening. J Clin Oncol 2009 0.93
75 Cost minimization study of image-guided core biopsy versus surgical excisional biopsy for women with abnormal mammograms. J Clin Oncol 2004 0.93
76 Process evaluation in an intervention designed to improve rates of colorectal cancer screening in a VA medical center. Health Promot Pract 2007 0.92
77 Strategies to improve repeat fecal occult blood testing cancer screening. Cancer Epidemiol Biomarkers Prev 2013 0.92
78 US hospital care for patients with HIV infection and pneumonia: the role of public, private, and Veterans Affairs hospitals in the early highly active antiretroviral therapy era. Chest 2004 0.91
79 A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians. Gynecol Oncol 2004 0.91
80 Ethnic variation in localized prostate cancer: a pilot study of preferences, optimism, and quality of life among black and white veterans. Clin Prostate Cancer 2004 0.90
81 Nighttime and weekend medication error rates in an inpatient pediatric population. Ann Pharmacother 2010 0.89
82 A rapid staging system for predicting mortality from HIV-associated community-acquired pneumonia. Chest 2003 0.89
83 TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology. Transplantation 2002 0.89
84 Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2007 0.89
85 Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen. Ann Intern Med 2002 0.88
86 Surgery and adjuvant chemotherapy use among veterans with colon cancer: insights from a California study. J Clin Oncol 2010 0.88
87 Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res 2011 0.88
88 Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy 2011 0.88
89 Agreement between prostate cancer patients and their clinicians about utilities and attribute importance. Health Expect 2004 0.88
90 Mind the gap: racial differences in breast cancer incidence and biologic phenotype, but not stage, among low-income women participating in a government-funded screening program. Breast Cancer Res Treat 2012 0.87
91 Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs. J Clin Oncol 2005 0.87
92 Local perspective of the impact of the HIPAA privacy rule on research. Cancer 2006 0.87
93 Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2008 0.87
94 Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med 2004 0.85
95 Enforcement actions involving Medicaid fraud and abuse, 1996-2009. Arch Intern Med 2011 0.85
96 Erythropoietin, a novel repurposed drug: an innovative treatment for wound healing in patients with diabetes mellitus. Wound Repair Regen 2013 0.85
97 Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating. Leuk Lymphoma 2009 0.84
98 Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2008 0.84
99 Feasibility and effectiveness of the NEST13+ as a screening tool for advanced illness care needs. J Palliat Med 2010 0.83
100 Delays in suspicion and isolation among hospitalized persons with pulmonary tuberculosis at public and private US hospitals during 1996 to 1999. Chest 2005 0.83
101 Genotyping and functional analysis of the D104N variant of human endostatin. Cancer Biol Ther 2004 0.83
102 Proxy assessment of health-related quality of life in african american and white respondents with prostate cancer: perspective matters. Med Care 2009 0.83
103 Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. Semin Dial 2008 0.82
104 Opportunities for disease state management in prostate cancer. Dis Manag 2005 0.82
105 When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective? J Clin Oncol 2006 0.82
106 Evaluation of a potential clinical interaction between ceftriaxone and calcium. Antimicrob Agents Chemother 2010 0.82
107 Quality of life after a diagnosis of prostate cancer among men of lower socioeconomic status: results from the Veterans Affairs Cancer of the Prostate Outcomes Study. Urology 2003 0.82
108 Relationship between health insurance and medical care for patients hospitalized with human immunodeficiency virus-related Pneumocystis carinii pneumonia, 1995-1997: Medicaid, bronchoscopy, and survival. Clin Infect Dis 2003 0.82
109 Evaluating the total costs of cancer. The Northwestern University Costs of Cancer Program. Oncology (Williston Park) 2003 0.81
110 Vision insurance, eye care visits, and vision impairment among working-age adults in the United States. JAMA Ophthalmol 2013 0.80
111 Dermatologic challenges in cancer patients and survivors. Oncology (Williston Park) 2007 0.80
112 Invited commentary: Prostate cancer: doing less might be more. Comment on "Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer". Arch Intern Med 2010 0.80
113 Merging claims databases with a tumor registry to evaluate variations in cancer mortality: results from a pilot study of 698 colorectal cancer patients treated at one hospital in the 1990s. Cancer Invest 2004 0.80
114 Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012 0.79
115 Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. Best Pract Res Clin Haematol 2005 0.79
116 Heeding our words: complexities of research among low-literacy populations. J Clin Oncol 2009 0.79
117 Single- versus multiple-tablet HIV regimens: adherence and hospitalization risks. Am J Manag Care 2016 0.79
118 Discriminating inhalational anthrax from community-acquired pneumonia using chest radiograph findings and a clinical algorithm. Chest 2007 0.79
119 Pharmaceutical fraud and abuse in the United States, 1996-2010. Arch Intern Med 2011 0.79
120 Cost considerations in the management of cancer in the older patient. Oncology (Williston Park) 2007 0.79
121 HIV-related pneumonia care in older patients hospitalized in the early HAART era. AIDS Patient Care STDS 2004 0.78
122 Will newer anticoagulants improve therapy persistence? Arch Intern Med 2012 0.78
123 Thrombotic thrombocytopenic purpura-2005. Semin Thromb Hemost 2005 0.78
124 Sildenafil- and tadalafil-associated optic neuropathy: implications for men after prostate cancer treatment. Community Oncol 2009 0.78
125 Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review. Best Pract Res Clin Haematol 2005 0.78
126 Cancer patients' use of pharmaceutical patient assistance programs in the outpatient pharmacy at a large tertiary cancer center. Community Oncol 2012 0.77
127 Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication. Expert Opin Drug Saf 2011 0.77
128 Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR). Br J Haematol 2013 0.77
129 G-CSF as prophylaxis of febrile neutropenia in SCLC. Expert Opin Pharmacother 2002 0.77
130 Clinical characteristics of erythropoietin-associated pure red cell aplasia. Best Pract Res Clin Haematol 2005 0.77
131 The excessive cost of early stage bladder cancer care: are providers really to blame? Cancer 2010 0.77
132 Gadolinium-associated nephrogenic systemic fibrosis. Community Oncol 2008 0.77
133 Sustaining mammography screening among the medically underserved: a follow-up evaluation. J Womens Health (Larchmt) 2015 0.76
134 Six years after. Acta Radiol 2012 0.76
135 Cardiac risks associated with antibiotics: azithromycin and levofloxacin. Expert Opin Drug Saf 2014 0.76
136 Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis. J Natl Cancer Inst 2013 0.76
137 Pilot study of a utilities-based treatment decision intervention for prostate cancer patients. Clin Prostate Cancer 2002 0.76
138 Editorial comment. Urology 2012 0.75
139 Risks of Venous Thromboembolism and Mortality Associated With Erythropoiesis-Stimulating Agents for the Treatment of Cancer-Associated Anemia. Am J Hematol Oncol 2008 0.75
140 Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the chicago metropolitan area: impact of timing and surge capacity. Biosecur Bioterror 2012 0.75
141 Editorial comment. Urology 2010 0.75
142 Reply to W. Read. J Clin Oncol 2014 0.75
143 AIs: implications for fractures in perimenopausal women with breast cancer. Community Oncol 2008 0.75
144 Screening colonoscopy vs flexible sigmoidoscopy. JAMA 2010 0.75
145 Geography: an increasingly important variable in prostate cancer clinical trials. BJU Int 2015 0.75
146 Reducing adverse drug events in the outpatient chemotherapy setting: attention must be paid. Cancer 2005 0.75
147 Editorial comment. Urology 2013 0.75
148 Adverse drug interactions: moving from perception to action. Pharmacoeconomics 2010 0.75
149 Editorial comment. Urology 2013 0.75
150 Joint breast and colorectal cancer screenings in medically underserved women. J Community Support Oncol 2015 0.75
151 Editorial comment. Urology 2012 0.75
152 Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012 0.75
153 Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS One 2012 0.75
154 Colony-stimulating factors for febrile neutropenia. N Engl J Med 2013 0.75
155 Upping recruitment in clinical trials: are the costs worth it? Onkologie 2009 0.75
156 Forewarned is forearmed: erythropoietin use in CKD patients with cancer. J Nephrol 2013 0.75
157 Low-molecular-weight heparins: do we have the GUSTO to identify differences between alternative formulations? Arch Intern Med 2005 0.75
158 Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited. Pharmacoeconomics 2005 0.75
159 Adverse effects of drugs on hemostasis and thrombosis. Semin Thromb Hemost 2012 0.75
160 Partnering to promote equality in cancer care. Soc Work Public Health 2009 0.75
161 Cost-effectiveness considerations in the treatment of essential thrombocythemia. Semin Oncol 2002 0.75
162 Does reimbursement affect physicians' decision making? Examples from the use of recombinant erythropoietin. Cancer Treat Res 2008 0.75
163 Emerging drugs for treatment of anemia of chronic kidney disease. Expert Opin Emerg Drugs 2013 0.75
164 Tackling community-acquired methicillin-resistant Staphylococcus aureus in collegiate football players following implementation of an anti-MRSA programme. Br J Sports Med 2013 0.75
165 Racial variations in care and outcomes for inpatient HIV-related pneumocystis pneumonia. J Health Care Poor Underserved 2010 0.75
166 Selection of contraceptive therapy for patients with thrombophilia: a review of the evidence. J Womens Health (Larchmt) 2014 0.75